Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olpasiran in Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
NCT07293260Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Mar 2026
- Primary completion
- Jun 2028
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 11
01
Overview
A Phase 3 trial of olpasiran in atherosclerotic cardiovascular disease (ASCVD), sponsored by Amgen. Started Mar 2026; status: recruiting.
02
Drugs
olpasiran
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT07293260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07293260.